AdvisorShares Pure Cannabis ETF (YOLO)

Key Updates

YOLO declined 5.91% to $2.55 since the April 1st report, erasing the prior session's 2.28% recovery and establishing a new multi-month low. The ETF now trades 22.73% below its 2026 starting level, with accelerating bearish momentum across all timeframes. Two significant sector developments emerged: Mary's Medicinals announced participation in a new CMS trial program for cannabinoid therapies beginning 2027, representing potential regulatory advancement, while Cambria liquidated its competing cannabis ETF (TOKE) effective April 2026, signaling continued institutional retreat from the sector. The cannabis investment landscape remains challenged despite isolated product innovation announcements.

Current Trend

YOLO exhibits severe bearish momentum with the 1-month decline of 11.76% accelerating to 27.76% over six months. The current price of $2.55 represents a fresh low in the available data series, breaking below the March 20th and March 27th support at $2.65. The ETF has declined in 7 of the last 8 sessions, with brief recoveries consistently failing. YTD performance of -22.73% significantly underperforms broader equity markets, indicating sector-specific headwinds beyond general market conditions. Technical structure shows no established support levels, with price action suggesting capitulation selling and institutional exit flows.

Investment Thesis

The cannabis sector investment thesis centers on federal legalization catalysts, state market expansion, and institutional capital allocation. However, the thesis faces mounting challenges: federal reform remains stalled with no concrete legislative timeline, institutional participants are actively exiting (evidenced by TOKE liquidation), and major operators are diversifying away from cannabis (Tilray's beverage focus). Positive developments include the CMS cannabinoid trial program, which could establish medical legitimacy and reimbursement pathways by 2027, and continued product innovation from operators like Curaleaf and Organigram. The sector's viability increasingly depends on demonstrating profitability under current regulatory constraints rather than awaiting federal reform.

Thesis Status

The investment thesis has materially deteriorated since the last report. The Cambria Cannabis ETF liquidation represents a significant negative signal, as institutional asset managers abandon the sector due to sustained underperformance and limited investor demand. This directly contradicts the thesis requirement for institutional capital inflows. Conversely, the CMS trial program announcement provides the first tangible federal regulatory advancement in months, potentially validating medical cannabis applications and creating reimbursement pathways. However, implementation begins in 2027, offering no near-term catalyst. The thesis remains under pressure with negative price action reflecting deteriorating fundamentals and investor sentiment.

Key Drivers

The primary negative driver is institutional capital flight, exemplified by the Cambria Cannabis ETF liquidation, which signals sustained underperformance and diminishing investor interest in cannabis exposure. Major operators are diversifying away from cannabis, with Tilray's BrewDog acquisition highlighting that cannabis now represents only 31% of its revenue versus 37% for beverages and distribution. The positive catalyst is the CMS cannabinoid trial program, which establishes federal recognition of cannabinoid therapies through Medicare/Medicaid channels and could drive medical legitimacy. Product innovation continues with Curaleaf's Select Briq 2 launch across 13 states and Organigram's SHRED Shotz leveraging a brand with $200 million in 2025 retail sales, demonstrating operational execution despite sector headwinds.

Technical Analysis

YOLO trades at $2.55, a new low in the available data series, with no established support levels visible. The ETF broke below the $2.65 level that provided temporary support on March 20th and March 27th, indicating accelerating downside momentum. Resistance now sits at $2.65, with additional resistance at $2.71 (April 1st high) and $2.80 (March 26th recovery high). The price structure shows consistent lower highs and lower lows, defining a clear downtrend channel. Volume patterns suggest distribution rather than accumulation, with brief recovery attempts met with increased selling pressure. The 1-month decline of 11.76% accelerating to 22.73% YTD indicates deteriorating technical momentum across all timeframes. Without a catalyst to reverse institutional selling pressure, technical indicators point to continued downside risk with potential tests of the $2.40-$2.50 zone.

Bull Case

• CMS cannabinoid trial program establishes federal recognition through Medicare/Medicaid channels, creating medical legitimacy and potential reimbursement pathways beginning 2027, which could fundamentally shift institutional perception of cannabis as a validated therapeutic category. Source
• Major operators demonstrate continued execution with product innovation, including Curaleaf's Select Briq 2 launching across 13 states addressing a market where 58% of vape users seek improved solutions, and Organigram's SHRED brand surpassing $200 million in retail sales, indicating strong consumer demand despite sector headwinds. Source and Source
• Cannabis wellness products target massive addressable markets, with Smokiez expanding CBN sleep formulations to address 50-70 million Americans suffering from chronic sleep disorders according to CDC data, positioning cannabis as an alternative to pharmaceutical sleep aids. Source
• Current valuation at $2.55 represents a 22.73% YTD decline and 27.76% six-month decline, potentially offering entry points for contrarian investors if federal reform catalysts materialize or institutional sentiment shifts following the CMS program implementation. Source
• Sector consolidation through competitor exits like the Cambria Cannabis ETF liquidation could concentrate capital flows into remaining vehicles like YOLO, potentially reducing competition for investor allocations in cannabis-focused investment products. Source

Bear Case

• Institutional capital flight exemplified by Cambria liquidating its Cannabis ETF signals sustained underperformance and diminishing investor demand, with TOKE representing failed institutional commitment to the sector and validating concerns about cannabis investment viability under current regulatory constraints. Source
• Major cannabis operators are actively diversifying away from cannabis, with Tilray reducing cannabis to only 31% of revenue while expanding beverages and distribution, indicating that management teams view cannabis as insufficient for growth and profitability, undermining sector investment thesis. Source
• Technical breakdown to new lows at $2.55 with accelerating momentum across all timeframes (1-month -11.76%, 6-month -27.76%, YTD -22.73%) indicates capitulation selling and absence of institutional support, with no visible support levels suggesting further downside risk. Source
• CMS trial program implementation timeline extends to 2027 with patient access through LEAD model, providing no near-term catalyst while sector continues deteriorating, and program limited to products with up to 3mg THC per serving, restricting commercial impact to narrow wellness segment. Source
• Tilray's stock performance falling below $1 in 2025 and facing Nasdaq delisting risk demonstrates that even diversified cannabis operators with significant non-cannabis revenue streams struggle with profitability and investor confidence, suggesting structural sector challenges beyond regulatory issues. Source